Genomic Analysis of CALGB 40601 for HER2-Positive Breast Cancer

Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022Подробнее

Independent validation of the HER2DX genomic test in HER2-positive breast cancerПодробнее

Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast CancerПодробнее

Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast CancerПодробнее

The genomic characterization of primary and metastatic HER2-low breast cancersПодробнее

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast CancerПодробнее

Dr. Hudis Discusses the CALGB 40601 Study in Breast CancerПодробнее

CALGB 40601 Alliance: impact of dual HER2 targeting on pCRПодробнее

Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast CancerПодробнее

EA1181/CompassHER2 pCR Research Study for HER2-Positive Breast Cancer - Full VideoПодробнее

Utilizing Genomic Assays for Decision Making in Early Stage Breast CancerПодробнее

Comprehensive genomic profiling in tumour analysisПодробнее

Genomic Profiling For Breast Cancer Patients Undergoing ImmunotherapyПодробнее

Dr. Simon on Genomic Assays for Patients With Breast CancerПодробнее

Genomic and transcriptomic landscape of HER2-low breast cancerПодробнее

The HER Pathway and CancerПодробнее

Immunotherapy Combination in HER2-Positive Breast CancerПодробнее

Genomic Biomarker for Predicting Response in Early Breast Cancer PatientsПодробнее

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast CancerПодробнее